Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01147939 · ClinicalTrials.gov registry record · Phase 3

Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)

A Phase 3 study of Acute Myeloid Leukemia (AML), sponsored by Clavis Pharma.

Completed
Registry status
Phase 3
Development phase
381
Enrollment target
20
Study locations

NCT01147939 is a Phase 3 study of Acute Myeloid Leukemia (AML) that has completed, run by Clavis Pharma. The registered enrollment target is 381 participants, above the 132-participant average among 29 other Acute Myeloid Leukemia (AML) trials with a reported enrollment target (189% higher). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01147939, a Phase 3 study of Acute Myeloid Leukemia (AML), has completed, sponsored by Clavis Pharma.

COMPLETED
Registry status
Phase 3
Development phase
381 participants
Enrollment target
20
Study locations

Study Summary

The purpose of the study is to assess the efficacy and safety of elacytarabine versus investigator's choice treatment in patients with relapsed or refractory acute myeloid leukemia (AML).

Conditions Studied

Acute Myeloid Leukemia (AML)

Interventions

  • DRUG Investigator's Choice
  • DRUG Elacytarabine

Study Locations (20)

California

  • Scripps Cancer Center Clinical Research - La Jolla
  • USC/Norris Comprehensive Cancer Center and Hospital - Los Angeles
  • UCLA School of Medicine, Division of Hematology/Oncology - Los Angeles

New York

  • New York Presbyterian Hospital, Weill-Cornell Medical College - New York
  • Memorial Sloan-Kettering - New York
  • New York Medical College - Valhalla

Georgia

  • Winship Cancer Institute at Emory - Atlanta
  • The Blood and Marrow Transplant Group of GA - Atlanta

Illinois

  • Northwestern University - Chicago
  • Rush University Medical Center - Chicago

North Carolina

  • Duke University Medical Center - Durham
  • Wake Forest University, Health Sciences Section on Hematology and Oncology - Winston-Salem

Colorado

  • Rocky Mountain Blood and Bone Marrow Transplant Program - Denver

Florida

  • Shands at the University of Florida - Gainesville

Indiana

  • St. Francis Hospital and Health Center - Indianapolis

Trial Details

FieldValue
Enrollment Target 381 participants
Start Date 2010-06
Est. Completion 2013-06
Phase Phase 3

Sponsor

Clavis Pharma

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01147939

The ClinicalTrials.gov registry entry for NCT01147939 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 381 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 132-participant average among 29 other Acute Myeloid Leukemia (AML) trials with a reported enrollment target (189% higher). The listed sponsor is Clavis Pharma, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acute Myeloid Leukemia (AML) appearing as the primary indexed condition, and to 2 interventions - of which Investigator's Choice is the first listed.

NCT01147939 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, New York, Georgia.

Frequently Asked Questions

What is clinical trial NCT01147939 about?

NCT01147939 is a clinical study titled "Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)". The purpose of the study is to assess the efficacy and safety of elacytarabine versus investigator's choice treatment in patients with relapsed or refractory acute myeloid leukemia (AML).

What is the current status of trial NCT01147939?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 381 participants. The study started on 2010-06. Estimated completion is 2013-06.

What conditions does trial NCT01147939 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia (AML).

What interventions are being tested in trial NCT01147939?

The interventions under investigation include: Investigator's Choice (DRUG), Elacytarabine (DRUG).

Who is sponsoring clinical trial NCT01147939?

This trial is sponsored by Clavis Pharma, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01147939 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myeloid Leukemia (AML)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Myeloid Leukemia (AML)

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.